These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21692697)

  • 1. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
    Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL
    Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
    Gardner TA; Elzey BD; Hahn NM
    Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
    Paller CJ; Antonarakis ES
    Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
    Bulloch MN; Elayan MM; Renfroe HR
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
    Wesley JD; Whitmore J; Trager J; Sheikh N
    Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
    Madan RA; Schwaab T; Gulley JL
    J Natl Compr Canc Netw; 2012 Dec; 10(12):1505-12. PubMed ID: 23221788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
    Madan RA; Gulley JL
    Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two years of Provenge.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Apr; 8(4):505. PubMed ID: 22832253
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaco-economic aspects of sipuleucel-T.
    Simoens S
    Hum Vaccin Immunother; 2012 Apr; 8(4):506-8. PubMed ID: 22336882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL
    Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.